Topic
Minoxidil forms compared
Solution, foam, oral tablets, sublingual and extended-release minoxidil deliver the same drug in different ways; this page compares them.
Key takeaways
- Topical 5% is the proven, cheap default for men and women. In men 5% beat 2% in 393 men (Olsen 2002); in women a Cochrane review found no 2% versus 5% difference (van Zuuren 2016).
- Foam versus solution: foam is propylene-glycol-free, so it causes less itch and flaking. Once-daily 5% foam matched twice-daily 2% solution in 322 women (+23.9 versus +24.2 hairs/cm2), though the non-inferiority margin was narrowly missed (Blume-Peytavi 2016).
- Higher strengths do not help: 10% was no better than 5% and more irritating in 90 men (Ghonemy 2021).
- Oral is not clearly better. Every direct trial found no significant density difference, including 90 men (Penha 2024), and a 2025 meta-analysis of four RCTs (279 people) found about double the hypertrichosis risk on oral (Sobral 2025).
- Dose: in 100 men, 2.5 mg matched 5 mg over 24 weeks with fewer side effects (Carvalho 2025).
- Sublingual 5 mg matched oral 5 mg in 110 men, with fewer palpitations (0% versus 9.3%) (Sanabria 2025); a phase 3 finished in May 2026 with no results posted.
- Extended-release oral (VDPHL01) was reported by its company to give +30 to +33 versus +7 hairs/cm2 at 6 months in men; it is not peer reviewed (trial record).
- Compounded capsules carry dosing-error risk: twelve severe reactions among about 1,700 prescriptions, one stroke after 1,000 mg instead of 1 mg (Moreno-Arrones 2022).
- Stopping reverses the benefit for every form (Price 1999).
The science
| Form | Strength / dose | Access | Evidence | Best for | Main downsides |
|---|---|---|---|---|---|
| Solution | 2%, 5% twice daily | Over the counter in the US and UK, mostly in the EU | Several large RCTs and meta-analyses | First line, lowest cost | Alcohol and propylene glycol itch, greasy styling, facial hair in women |
| Foam | 5% twice daily (men), once daily (women) | Over the counter (US, UK) | RCT in 352 men; women's trials | Sensitive or itchy scalps, styling | Flammable; same absorption warnings; somewhat dearer |
| Oral tablet, low dose | 1.25 to 5 mg/day (common ranges) | Prescription, off-label for hair | Small RCTs equal to topical; a 1,404-patient safety cohort (Vañó-Galván 2021) | People who skip topicals, scalp inflammation, plateau | Extra body hair, ankle swelling, dizziness; contraindicated in pregnancy |
| Compounded capsule | any | Common outside the US | Same drug; no separate trials | Only where tablets are unavailable | Dosing errors |
| Sublingual | 0.45 to 5 mg | Investigational | Phase 1b and a 110-man RCT | Possibly fewer palpitations | Evidence mostly from one group with patents |
| Extended-release oral | 4.5 to 8.5 mg | Investigational | Company press release | Once-daily steady dosing | Unpublished |
Choosing by profile
- Men, crown thinning: topical 5% foam or solution; add finasteride for more. The combination improved 94.1% of 450 men versus 80.5% on finasteride and 59% on minoxidil (Hu 2015).
- Women: 5% foam once daily or 2% solution twice daily; facial hair is the main limit. Women develop hypertrichosis on oral minoxidil at lower doses than men, and pregnancy and breastfeeding rule it out.
- Hairline and temples: minoxidil can thicken miniaturised hairs but cannot regrow follicles that are gone; the US men's label covers the vertex only (label).
- Curly, coily, thick or dry hair: solutions can leave residue and itch; foam or a lightweight vehicle may suit. No hair-type-specific trials were found.
- Scalp irritation or dandruff: patch testing usually implicates propylene glycol rather than minoxidil, so propylene-glycol-free foam is the usual switch.
- Cat owners: topical minoxidil is toxic to cats; 8 of 62 symptomatic cats died in a poison-centre series (Tater 2021).
What it means by hair profile
See "Choosing by profile". Scalp type, curl pattern and porosity were not stratified in the trials found.
Myths and facts
- Myth: oral minoxidil is far stronger than topical. Fact: direct trials show similar density gains.
- Myth: more minoxidil, faster results. Fact: the US labels say using more will not improve results (label).
- Myth: the initial shed means it is not working. Fact: temporary shedding in the first weeks is common.
- Myth: a SULT1A1 test or booster guarantees results. Fact: the evidence comes mostly from the company that sells them, and tretinoin adds irritation without proven benefit.
Practical recommendations
- Give any form 4 to 6 months before judging it: the men's label says 2 to 4 months for first results, and the women's foam label says some women need at least 6 months (label).
- Use it consistently. Weighing oral minoxidil is a decision for a prescriber: it is off-label, and a 2025 consensus lists contraindications (past pericardial effusion, heart failure, pregnancy) and recommends low starting doses (Akiska 2025).
Bottom line
Start with topical 5% (foam if your scalp itches). Oral, sublingual and extended-release forms mainly offer convenience, not stronger regrowth, and add heart-rate, swelling and body-hair trade-offs. Discuss with a doctor before using oral minoxidil. See minoxidil for the full evidence.
Studies 19
Olsen EA et al. A randomized clinical trial of 5% topical minoxidil versus 2% topical minoxidil and placebo in the treatment of androgenetic alopecia in men. J Am Acad Dermatol. 2002
Tested: 5% vs 2% topical minoxidil solution vs placebo, twice daily
Result: 5% was superior to 2% and placebo, with about 45% more regrowth than 2% at week 48 and faster onset; itch and irritation were more common with 5%.
Read the study ↗van Zuuren EJ et al. Interventions for female pattern hair loss. Cochrane Database Syst Rev. 2016
Tested: topical minoxidil and other treatments vs placebo
Result: Minoxidil gave about 13.2 more hairs/cm2 than placebo; there was no difference between 2% and 5% in women.
Read the study ↗Blume-Peytavi U et al. Efficacy and safety of once-daily minoxidil foam 5% versus twice-daily minoxidil solution 2% in female pattern hair loss: a phase III study. 2016
Tested: 5% foam once daily vs 2% solution twice daily
Result: Gains were +23.9 vs +24.2 hairs/cm2; the prespecified non-inferiority margin was narrowly missed.
Read the study ↗Ghonemy S et al. Efficacy and safety of a new 10% topical minoxidil versus 5% topical minoxidil and placebo in male androgenetic alopecia. 2021
Tested: 10% vs 5% topical minoxidil vs placebo
Result: 10% was not better than 5% and was more irritating.
Read the study ↗Penha MA et al. Oral minoxidil vs topical minoxidil for male androgenetic alopecia: a randomized clinical trial. JAMA Dermatol. 2024
Tested: oral minoxidil 5 mg vs topical 5% twice daily, double-dummy
Result: No significant difference in terminal hair density; oral looked better only on vertex photographs; hypertrichosis affected 49% on oral.
Read the study ↗Asilian A et al. Clinical efficacy and safety of low-dose oral minoxidil versus topical solution in androgenetic alopecia: a randomized controlled trial. 2024
Tested: oral minoxidil 1 mg vs topical 5%
Result: No significant difference between oral and topical; topical was numerically better.
Read the study ↗Show 13 more studies
Vahabi-Amlashi S et al. A randomized clinical trial on therapeutic effects of 0.25 mg oral minoxidil tablets on treatment of female pattern hair loss. 2021
Tested: oral minoxidil 0.25 mg vs topical 2%
Result: Both improved (oral from 102 to 115 hairs/cm2) with no difference between groups.
Read the study ↗Sobral et al. Efficacy and safety of oral minoxidil versus topical solution in androgenetic alopecia: a meta-analysis of randomized clinical trials. 2025
Tested: oral vs topical minoxidil
Result: Hair density did not differ (standardised difference 0.02); oral roughly doubled the risk of hypertrichosis (relative risk 2.01).
Read the study ↗Carvalho et al. Oral minoxidil 2.5 mg versus 5 mg for male androgenetic alopecia: a double-blind randomized clinical trial. 2025
Tested: oral minoxidil 2.5 mg vs 5 mg
Result: No difference in non-vellus hair density (0.9 hairs/cm2); ankle swelling and dizziness were more common on 5 mg.
Read the study ↗Sanabria B et al. Sublingual minoxidil 5 mg versus oral minoxidil 5 mg for male androgenetic alopecia: a double-blind randomized clinical trial. 2025
Tested: sublingual vs oral minoxidil 5 mg
Result: Same efficacy (total density +24.5 vs +21.8 per cm2) with fewer palpitations on sublingual (0% vs 9.3%).
Read the study ↗ClinicalTrials.gov NCT06724614. Extended-release oral minoxidil (VDPHL01) in men with pattern hair loss, phase 2/3. Veradermics
Tested: extended-release oral minoxidil vs placebo
Result: The company reported +30.3 and +33.0 vs +7.3 non-vellus hairs/cm2 at 6 months in a press release in April 2026; no peer-reviewed paper yet.
Read the study ↗Moreno-Arrones OM et al. Serious adverse effects from compounding errors with low-dose oral minoxidil for alopecia treatment. 2022
Tested: compounded low-dose oral minoxidil
Result: Twelve severe reactions (0.7% of about 1,700 prescriptions) came from capsules holding 10 to 100 times the prescribed dose.
Read the study ↗Hu R et al. Combined treatment with oral finasteride and topical minoxidil in male androgenetic alopecia: a randomized comparative study in Chinese patients. 2015
Tested: finasteride vs 5% minoxidil vs both
Result: Improved: 80.5% on finasteride, 59% on minoxidil, 94.1% on the combination.
Read the study ↗Tater KC et al. Topical minoxidil exposures and toxicoses in dogs and cats: 211 cases (2001-2019). J Am Anim Hosp Assoc. 2021
Tested: accidental exposure to topical minoxidil
Result: Signs followed even a few drops or licks; 8 of 62 symptomatic cats died.
Read the study ↗Vano-Galvan S et al. Safety of low-dose oral minoxidil for hair loss: a multicenter study of 1404 patients. 2021
Tested: low-dose oral minoxidil
Result: Hypertrichosis 15.1%, lightheadedness 1.7%, fluid retention 1.3%, fast heartbeat 0.9%; 1.7% stopped for side effects and no life-threatening events occurred.
Read the study ↗Akiska YM et al. Low-dose oral minoxidil initiation for patients with hair loss: an international modified Delphi consensus statement. JAMA Dermatol. 2025
Tested: low-dose oral minoxidil practice
Result: Common starting doses were 1.25 mg/day in adult women and 2.5 mg/day in adult men; pregnancy, past pericardial effusion and heart failure were contraindications.
Read the study ↗Price VH et al. Changes in hair weight and hair count in men with androgenetic alopecia after application of 5% and 2% topical minoxidil, placebo, or no treatment. J Am Acad Dermatol. 1999
Tested: 5% or 2% topical minoxidil vs placebo vs no treatment
Result: About 30% hair-weight gain was maintained while treated and was lost within 24 weeks of stopping.
Read the study ↗Minoxidil 5% topical foam for women, over-the-counter drug facts. DailyMed
Tested: 5% minoxidil foam, half a capful once daily
Result: Results may appear at 3 months and some women need at least 6 months; hair loss begins again if use stops; the foam is extremely flammable and may be harmful in pregnancy or breastfeeding.
Read the study ↗Minoxidil 5% topical foam for men, over-the-counter drug facts. DailyMed
Tested: 5% minoxidil foam, half a capful twice daily
Result: Labelled for regrowth on the top of the scalp (vertex) only, not for a receding hairline; using more or more often will not improve results.
Read the study ↗Related
- MinoxidilThe most widely used hair-growth treatment, available as a cheap over-the-counter lotion or foam and as a prescription tablet, with a mechanism that is still only partly understood.
- TretinoinA prescription acne and anti-ageing cream used off-label as a minoxidil booster because it increases minoxidil absorption, though the one randomised trial found no extra hair benefit.
- Topical cetirizineThe common allergy antihistamine, made up as a 1% scalp solution, has several small trials suggesting a modest effect that is weaker than minoxidil.
- FinasterideA prescription pill (and in some countries a scalp spray) that lowers DHT and is the best-proven drug for stopping male pattern hair loss.
- Hair growth pipeline (2026)What is in clinical trials for hair loss as of October 2026, how far along it is, and how much to trust the early numbers.